<DOC>
	<DOCNO>NCT00326209</DOCNO>
	<brief_summary>To evaluate long-term safety tolerability mesalamine pellet ( MP ) patient ulcerative colitis currently remission .</brief_summary>
	<brief_title>Long-Term Safety Tolerability Mesalamine Pellets Patients With Ulcerative Colitis Remission</brief_title>
	<detailed_description>This Phase 3 , multicenter , open-label , treatment extension study evaluate long-term safety tolerability encapsulate mesalamine pellet ( MP ) give QD subject successfully participate previous MP study subject currently remission symptom ulcerative colitis .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . An Institutional Review Board ( IRB ) /Ethics Committee ( EC ) approve informed consent sign date prior studyrelated activity . 2 . Subject successfully participate previous MP clinical study per investigator 's discretion successful participation minimally define compliant studyrelated procedure study drug dosing schedule previous study discontinue previous study due study drugrelated AE ( ) new subject : . Subject male , If subject female , eligible enter : Nonchildbearing potential ( ie , physiologically incapable become pregnant , include female undergone sterilization [ hysterectomy bilateral tubal ligation ] postmenopausal . For purpose study , postmenopausal define 1 year without menses ) ; OR , Childbearing potential , negative serum pregnancy test screen , heterosexually active , agree one following : ) Double barrier method contraception , specifically , use condom spermicide , 1 week prior study drug administration , throughout 6month Treatment Phase , 2week followup phase . ii ) Oral contraceptive administer least 2 monthly cycle prior study drug administration 6 month study drug administration administer 1 monthly cycle follow completion study . iii ) An intrauterine device ( IUD ) , insert qualified clinician , publish data show low expected failure rate &lt; 1 % per year ( IUDs meet criterion ) . iv ) Medroxyprogesterone acetate ( DEPOPROVERA ) administer minimum 1 monthly cycle prior study drug administration , 6 month study drug administration , administer 1 monthly cycle follow study completion . Norelgestromin/ ethinyl estradiol transdermal system ( Ortho Evra patch ) administer least 2 monthly cycle prior study drug administration administer 2 monthly cycle follow study completion v ) Partner undergone vasectomy subject monogamous relationship . The investigator responsible determine whether subject adequate birth control study participation . b . Subject ≥18 year age . c. Subject historically confirm diagnosis ( physician letter newly/recently diagnose medical record previously diagnose subject ) mild moderate UC remission &gt; 1 month &lt; 12 month . d. Confirmed current remission define : A screening rectal bleeding score 0 described Disease Activity Index ( DAI ) ( Sutherland Index ) 0 = None A screening sigmoidoscopy score 0 1 mucosal appearance describe ( Sutherland Index 0 = intact mucosa preserve distorted vessel 1 = Erythema , decrease vascular pattern , granularity , mucosal hemorrhage ( see ; Appendix 2 copy entire Index ) . 3 . Subject investigator consider potential benefit subject MP treatment . 4 . Subject capable willing comply study procedure . 1 . Subject condition circumstance would , opinion investigator , prevent completion study interfere analysis study result , include history noncompliance treatment visit . If new subject , follow additional exclusion criterion apply : 2 . Subject history allergy intolerance aspirin , mesalamine salicylate . 3 . Subject abnormal clinical lab result opinion investigator significant enough prevent subject 's enrollment study . 4 . Subject subject 's parent know phenylketonuria . 5 . Subject participate investigational drug device study within 30 day prior study screen . 6 . Subject show evidence current excessive alcohol consumption drug dependence . 7 . Subject uncontrolled , clinically significant renal disease manifest 1.5 × ULN serum creatinine blood urea nitrogen ( BUN ) level . 8 . Subject calculated creatinine clearance level &lt; 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>UC</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Inflammatory bowel disease</keyword>
	<keyword>IBD</keyword>
</DOC>